Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AF74 | ISIN: US44842L1035 | Ticker-Symbol: H7T1
Siehe auch HUTCHMED CHINA LIMITED
Frankfurt
28.03.24
08:00 Uhr
15,400 Euro
-0,100
-0,65 %
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
HUTCHMED CHINA LIMITED ADR Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED ADR 5-Tage-Chart
RealtimeGeldBriefZeit
15,10016,10028.03.
15,50015,70028.03.

Aktuelle News zur HUTCHMED CHINA LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoHutchmed cancer treatment indication accepted for review in China1
DoHutchmed lung cancer treatment accepted for review in China1
DoHutchmed China Ltd - Savolitinib sNDA Accepted in China-
DoHUTCHMED (China) Limited: HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC3- Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients - - If approved, would...
► Artikel lesen
DoHUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED ANNOUNCES SAVOLITINIB SNDA ACCEPTED IN CHINA FOR TREATMENT-NAIVE OR PREVIOUSLY TREATED PATIENTS WITH ...1
22.03.Hutchmed begins registration stage for sovleplenib phase 2/3 trial2
22.03.HUTCHMED Ltd - 6-K, Report of foreign issuer-
22.03.HUTCHMED (00013): LETTERS TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM: NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS1
22.03.HUTCHMED (00013): LETTERS TO REGISTERED SHAREHOLDERS AND REPLY FORM: NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS1
22.03.HUTCHMED (China) Limited: HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China46HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration...
► Artikel lesen
22.03.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED INITIATES REGISTRATION STAGE OF THE ESLIM-02 PHASE II/III TRIAL OF SOVLEPLENIB FOR WARM ANTIBODY AUTOIMMUNE ...1
14.03.Affimed N.V., Hutchmed, Annexon among healthcare movers29
14.03.HUTCHMED Ltd - 6-K, Report of foreign issuer-
14.03.HUTCHMED (00013): GRANT OF SHARE OPTIONS UNDER SHARE OPTION SCHEME AND AWARDS UNDER LONG TERM INCENTIVE PLAN1
14.03.Hutchmed China Ltd - LTIP and Share Option Scheme-
05.03.HUTCHMED (00013): VESTING OF AWARDS UNDER THE LONG TERM INCENTIVE PLAN1
05.03.Hutchmed China Ltd - Vesting of awards under the LTIP-
01.03.Hutchmed is back in black with US$100m3
28.02.EARNINGS: Hutchmed revenue surges, Craven House's loss widens1
28.02.HUTCHMED (00013): PUBLICATION OF FORM 20-F1
Seite:  Weiter >>
116 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1